Novartis Returns OUS Rights for Jetrea to ThromboGenics

September 22, 2017: By Jon Swedien

April 2014 OMP ThromboGenics’ JetreaThromboGenics regained full global rights to Jetrea after reaching an agreement with Novartis, whose subsidiary, Alcon, had held the rights outside the US (OUS), ThromboGenics announced Sept. 18.

Jetrea (ocriplasmin), launched in January 2013, is a one-time, single intravitreal injection to treat adults with symptomatic vitreomacular adhesion.

In 2012, ThromboGenics struck an agreement with Novartis to license Jetrea’s OUS rights to Alcon.

Under that agreement, ThromboGenics received an upfront payment of €75 million ($97.9 million, conversion March 16, 2012) and was eligible to receive up to €300 million ($391.5 million, conversion March 16, 2012) more in potential milestone payments.

Under the new agreement, Novartis will pay ThromboGenics €53.7 million ($64.1 million, conversion Sept. 18, 2017) in cash and make a forthcoming equity investment of €10 million ($11.1 million, conversion Sept. 18, 2017) in ThromboGenics capital, ThromboGenics said.

Following the agreement, ThromboGenics will have more than €120 million in cash, the Belgium firm said.

The agreement stipulates Alcon and Novartis will work closely with ThromboGenics to ensure continuity and access to Jetrea for existing and future customers, ThromboGenics said.

In March 2017, ThromboGenics announced it would take an impairment charge of €26.6 million to align its Jetrea goodwill value with continued lower-than-expected sales.

Novartis took an impairment charge of $119 million on Jetrea in 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility